文献速递慢阻肺哮喘

Th2高表达与肥大细胞基因特征与COPD激素敏感性相关

Th2 high and mast cell gene signatures are associated with corticosteroid sensitivity in COPD.
PubMed 文献 · Thorax · 2022-12-07

该研究基于Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease COPD研究,对46例接受30个月吸入糖皮质激素(ICS)±长效β2受体激动剂(LABA)治疗的COPD患者支气管活检转录组进行分析,评估哮喘来源的三个转录组相关簇(TAC)的分布与富集分数。结果显示TAC1(Th2高表达)富集分数在30个月治疗后显著降低,TAC2和TAC3不受影响;由TAC1中ICS应答基因构建的激素敏感特征富含肥大细胞特异性基因,且基线基因转录水平与30个月ICS±LABA治疗后RV/TLC %predicted变化相关。结论提示哮喘来源的痰转录组特征可在COPD支气管活检中重现,并识别出气道肥大细胞特征作为激素反应性的预测指标。

要点

  • COPD支气管活检可重现哮喘来源的TAC转录组特征,TAC1为Th2高表达型。
  • ICS±LABA治疗30个月后TAC1富集分数显著降低,TAC2和TAC3无变化。
  • TAC1来源的激素敏感特征富含肥大细胞特异性基因,与活检肥大细胞数正相关。

核心结论

  • 哮喘队列的痰转录组特征可在COPD支气管活检中重现,并识别出气道肥大细胞基因特征作为激素反应性的预测指标。

研究设计与样本

  • 研究纳入46例参与Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease COPD研究的COPD患者,接受30个月ICS±LABA治疗。
  • 采用基因集变异分析(GSVA)评估三个TAC在支气管活检转录组中的分布与富集分数(ES),并与治疗后纵向临床变量关联。
  • 使用差异基因表达与细胞卷积定义关键调控基因和细胞类型。

主要发现

  • COPD患者基线支气管活检中三个TAC特征表达范围广泛。
  • ICS±LABA治疗30个月后TAC1的ES显著降低,TAC2和TAC3的ES不受影响。
  • 由TAC1中ICS应答基因构建的激素敏感特征由单细胞RNA测序鉴定的肥大细胞特异性基因组成,与ICS±LABA后支气管活检肥大细胞数正相关。
  • 基线基因转录水平与30个月ICS±LABA治疗后RV/TLC %predicted变化相关。

临床怎么用

  • COPD患者基线支气管活检TAC1(Th2高表达/肥大细胞)特征可能用于识别对ICS±LABA治疗激素反应性更好的亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Severe asthma and chronic obstructive pulmonary disease (COPD) share common pathophysiological traits such as relative corticosteroid insensitivity. We recently published three transcriptome-associated clusters (TACs) using hierarchical analysis of the sputum transcriptome in asthmatics from the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort comprising one Th2-high inflammatory signature (TAC1) and two Th2-low signatures (TAC2 and TAC3). OBJECTIVE: We examined whether gene expression signatures obtained in asthma can be used to identify the subgroup of patients with COPD with steroid sensitivity. METHODS: Using gene set variation analysis, we examined the distribution and enrichment scores (ES) of the 3 TACs in the transcriptome of bronchial biopsies from 46 patients who participated in the Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease COPD study that received 30 months of treatment with inhaled corticosteroids (ICS) with and without an added long-acting β-agonist (LABA). The identified signatures were then associated with longitudinal clinical variables after treatment. Differential gene expression and cellular convolution were used to define key regulated genes and cell types. MEASUREMENTS AND MAIN RESULTS: Bronchial biopsies in patients with COPD at baseline showed a wide range of expression of the 3 TAC signatures. After ICS±LABA treatment, the ES of TAC1 was significantly reduced at 30 months, but those of TAC2 and TAC3 were unaffected. A corticosteroid-sensitive TAC1 signature was developed from the TAC1 ICS-responsive genes. This signature consisted of mast cell-specific genes identified by single-cell RNA-sequencing and positively correlated with bronchial biopsy mast cell numbers following ICS±LABA. Baseline levels of gene transcription correlated with the change in RV/TLC %predicted following 30-month ICS±LABA. CONCLUSION: Sputum-derived transcriptomic signatures from an asthma cohort can be recapitulated in bronchial biopsies of patients with COPD and identified a signature of airway mast cells as a predictor of corticosteroid responsiveness.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Faiz A, Pavlidis S, Kuo CH, et al. Th2 high and mast cell gene signatures are associated with corticosteroid sensitivity in COPD. Thorax. 2022. PMID: 36598042. doi:10.1136/thorax-2021-217736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。